Inhibrx Biosciences (INBX) Investor presentation summary

Mission and financial highlights

• Focus on discovering and developing biologic treatments for life-threatening conditions.

• $124.2M in cash and cash equivalents as of 12/31/2025.

• Over 300 patients treated with ozekibart (INBRX-109) and over 175 with INBRX-106.

• 14.6M common shares outstanding, 19.6M fully diluted.

• In-house expertise spans discovery, protein engineering, clinical development, and commercialization.

Strategic focus and upcoming milestones

• High internal ownership aligns interests with shareholders; 2026 milestones expected to drive value.

• Ozekibart transaction paused pending INBRX-106 Phase 2 Hexagon trial results.

• Potential ozekibart approval for metastatic or unresectable chondrosarcoma in 2H 2026.

• Interim ORR and PFS data for INBRX-106 in first-line HNSCC expected in 1H 2026.

• Potential FDA meeting for accelerated approval in refractory Ewing sarcoma and fourth-line CRC in 2H 2026.

INBRX-106: Next-generation OX40 agonist

• Designed as a hexavalent agonist to maximize OX40 signaling and antitumor activity.

• Demonstrates potent, dose-dependent expansion of CD4+ and CD8+ memory T cells.

• Phase 1 data show robust single-agent activity and foundation for combination efficacy.

• Combination with pembrolizumab shows tumor reduction and durable responses in NSCLC and HNSCC.

• Randomized Phase 2/3 Hexagon study in 1L HNSCC aims to demonstrate added benefit over pembrolizumab alone.